source
- Roche partners with Simcere Zaiming on trispecific T cell engager, $75M upfrontRoche announced a collaboration with Chinese biopharma Simcere Zaiming to develop a trispecific T cell engager aimed at cancer therapy. The agreement includes an upfront payment of $75 million to…
- ARCH Venture Partners aims to raise $3 billion for its 14th biotech fundARCH Venture Partners, a leading biotech venture capital firm, announced its intention to raise about $3 billion for a new fund. The proposed fund would be the firm's 14th and would rank among the…